A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
Advanced Cancer
DRUG: ZL-1201
Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events, Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0, From the time of informed consent to 30 days after last dose
Pharmacokinetics：AUC, The area under the curve (AUC) of serum concentration of the drug after the administration, Up to 30 days after last dose|Pharmacokinetics: Cmax, Maximum serum concentration(Cmax) of the drug after the administration, Up to 30 days after last dose|Pharmacokinetics: t1/2, Half-life(t1/2) of the drug, Up to 30 days after last dose|Pharmacokinetics: CL, Total body clearance of the drug, Up to 30 days after last dose|Pharmacokinetics: Vss, Volume of the distrubution at steady-state, Up to 30 days after last dose|Immunogenicity, Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity, Up to 30 days after last dose|Overall Response Rate (ORR）, ORR includes CR and PR, Up to 2 years after enrollment
This is a first-in-human, dose escalation trial of ZL-1201. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.